Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar pchop123 (79.63) Submitted: 11/27/2012 7:05:34 PM : Outperform Start Price: $2.81 DVAX Score: -4.78

somewhat attractive now at this price

Featured Broker Partners


Advertisement